Vessatis is a prescription medication indicated for the management of symptoms associated with certain chronic inflammatory conditions in adults. Its primary role is to support relief from discomfort, joint stiffness, and related functional limitations that can affect everyday routines. Clinical studies suggest that Vessatis may contribute to improving overall physical function in individuals with these conditions. The benefit provided is focused on reducing the severity of symptoms rather than curing the underlying condition. It is a therapeutic option used for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

Utilizing Vessatis can support a more comfortable lifestyle by helping to sustain mobility and diminish persistent discomfort, thus aiding in the maintenance of daily activities.

---

Quick Fact: Relief for Joint Discomfort Vessatis is intended to address persistent joint discomfort and stiffness linked to long-term inflammatory disease.

Who Can and Cannot Use Vessatis?

The eligibility for Vessatis (a lidocaine 5% medicated topical patch) is determined by specific regulatory requirements, focusing on patient age, known allergies, organ function, and the condition of the application site.

Populations for Whom Use is Contraindicated

Classification	Population/Condition
Absolute Contraindication	Known allergy or hypersensitivity to lidocaine, any component of the patch, or to other amide-type local anesthetics.
Application Restriction	Application to non-intact skin (e.g., inflamed, broken, wounded, or mucous membranes).

Age and Development Status

Vessatis is primarily intended for adults (18 years and older). Its safety and effectiveness have not been established in the pediatric population (patients under 18 years of age), and therefore, use is not recommended in this group. While older adults are eligible, caution is advised due to the higher potential for age-related reductions in liver, kidney, or heart function.

Condition-Based Eligibility Rules

Use requires caution in patients with severe hepatic (liver) disease due to an increased risk of toxic blood concentrations, as lidocaine is metabolized in the liver. Similarly, severe renal (kidney) impairment requires caution, as the drug's metabolites may accumulate. Caution is also advised when Vessatis is used in patients receiving Class I antiarrhythmic drugs.

Interactions with other medicines and products

The official regulatory information for Vessatis focuses on specific interactions that may affect safety and require caution or monitoring during co-administration.

---

Potential for Increased Central Nervous System (CNS) Effects

Do not use Vessatis with alcohol (ethanol). Concurrent use of Vessatis with alcohol is advised against due to the potential for increased CNS depressant effects, such as enhanced drowsiness, reduced alertness, and impairment of mental and motor performance.

Caution is required when Vessatis is used alongside other Central Nervous System (CNS) depressants. This includes specific classes of medicines such as certain sedatives, anxiolytics (anti-anxiety medications), opioid pain relievers, and sleeping aids. Co-administration may increase the risk of the depressant effects mentioned above.

---

Pharmacokinetic Interactions

Co-administration of Vessatis with theophylline has been documented to result in a decrease in the clearance of cetirizine, one of the active components of the product. This change in clearance may lead to increased plasma concentrations of cetirizine, and appropriate monitoring or dose adjustment may be necessary.

Lack of Clinically Significant Interaction

Official regulatory studies have concluded that there are no clinically significant pharmacokinetic interactions when cetirizine is co-administered with certain medications, including pseudoephedrine, azithromycin, erythromycin, or ketoconazole.

Mechanism: Targeted Blockade of Sensory Sodium Channels

The core action of Vessatis's active ingredient, Lidocaine, is classified as a voltage- and use-dependent blockade focused exclusively on the voltage-gated sodium channels ( Na^+ channels) found on peripheral sensory nerve fibers. This interaction stabilizes the channel in an inactive state, physically preventing the rapid sodium influx required for the nerve to generate an electrical impulse. This engagement of the Na^+ channel domain leads directly to functional cessation of action potential generation.

---

Pathway: Interruption of Peripheral Signal Conduction

By arresting the ability of the nerve cell to depolarize, the drug effectively operates within the domain of peripheral nociceptive signal transduction, suppressing the pathways responsible for transmitting sensory messages. This molecular action translates into the cellular consequence of non-propagating electrical activity in peripheral C-fibers and A-delta fibers. This targeted interruption of afferent signaling ensures the drug's effect profile is limited to the site of application, resulting in a localized physiological change.

---

Constraint: Strictly Peripheral and Concentration-Dependent Action

The drug's mechanism is fundamentally constrained by its peripheral and localized nature, meaning its Na^+ channel blockade only occurs where a sufficient concentration is achieved in the skin, avoiding any direct action on the central nervous system. This constraint is also subject to physiological limitations, such as reduced efficacy in acidic (low pH) tissues like inflamed areas, which can compromise the necessary molecular access to the nerve membrane.

Vessatis is a lidocaine 5% medicated plaster indicated for the symptomatic relief of neuropathic pain, such as that associated with post-herpetic neuralgia (PHN) following a shingles infection.

---

Application and Dosage

The plaster must be applied to intact, dry, non-irritated skin after the shingles lesions have healed. Do not apply to injured skin, open wounds, or unhealed blisters. The affected area should be covered with the plaster once daily for a maximum of 12 hours within a 24-hour period. The subsequent plaster-free interval must be at least 12 hours to minimize the potential for systemic exposure.

Feature	Instruction
Maximum Use	Up to three plasters may be used simultaneously, corresponding to the painful area.
Preparation	Any hair in the area should be cut with scissors, not shaved. The skin should be clean and dry.
Modification	If necessary, the plasters may be cut into smaller sizes with scissors before removing the release liner.
Adherence	The plaster must be applied immediately after removal from the sachet and pressed firmly onto the skin for at least 10 seconds. The sachet should be closed tightly after use to prevent the remaining plasters from drying out.

---

Re-evaluation of Treatment

Treatment benefit should be re-evaluated by a healthcare professional after 2 to 4 weeks. If there is no satisfactory response after this period, treatment discontinuation may be necessary, as the potential risks may outweigh the benefits.

Research Evidence / Overview of Studies for Vessatis

Evidence for Use in Overactive Bladder (OAB)

Research into Vessatis has been conducted mainly in adults diagnosed with Overactive Bladder (OAB), a condition characterized by fluctuating or episodic manifestations like urgency, frequency, and urge incontinence. Studies typically examined the use of Vessatis over defined time intervals, such as 12 weeks. These Randomized Controlled Trials (RCTs) monitored patient outcomes related to physical discomfort and daily functioning, measuring changes in the number of daily bladder voidings, urgency episodes, and urge incontinence episodes. Researchers also recorded the types and frequency of adverse events reported by participants during these defined study periods.

The findings describe patterns observed in the studies over the short term. Research highlights changes measured during the study period in these core OAB symptoms in the groups evaluated. Studies report how symptoms evolved in the observed populations, and findings describe patterns observed in the studies related to short-term changes in these measured outcomes in the studied groups. The evidence contributes to the broader evidence landscape by providing insight into short-term symptom patterns.

How Vessatis Was Studied Against Placebo and Other Treatments

The initial research included RCTs where Vessatis was evaluated in comparison to a placebo (an inactive treatment). These studies provided a baseline for understanding short-term symptom changes. Further research examined Vessatis in trials where it was studied alongside an existing therapy and not just placebo.

Long-Term Studies and Follow-Up Data

When considering extended use, the research includes open-label extension studies where patients were observed while participating for a longer time, up to one year. However, long-term patterns of evidence are not fully established. Follow-up durations were limited for the vast majority of patients, with the data beyond one year being highly restricted.

What is Still Uncertain About Vessatis Research

Despite the existing research, several areas remain where certainty is low or where more evidence is needed. Comparative evidence is lacking for many potential treatment options. Sample sizes were modest in some subgroup analyses, and evidence quality varies across studies. The data are still emerging to address these evidence gaps, and research provides context but not individual predictions regarding symptom response.

Key Studies & References Efficacy and Safety of Vessatis in Patients with Overactive Bladder (OAB): A 12-Week Phase 3 Randomized Controlled Trial

Common questions about Vessatis (FAQ)

---

Q: What is Vessatis and what is it used for?

A: Vessatis is a medicated plaster that contains the active ingredient lidocaine, a local anesthetic. It is used to provide symptomatic relief for a type of nerve pain called post-herpetic neuralgia (PHN) in adults. PHN is persistent pain that can occur after a shingles (Herpes Zoster) infection.

---

Q: How does Vessatis work?

A: Vessatis works in two ways:

• Pharmacological Action: The lidocaine in the plaster continuously diffuses into the skin, providing a local analgesic (pain-relieving) effect by reducing the pain signals in the skin.
• Mechanical Action: The plaster itself acts as a physical barrier, which helps to protect the painful, hypersensitive area of the skin from external stimuli and friction.

---

Q: How should I apply the Vessatis patch?

A: The Vessatis patch is applied directly to the painful area of skin. The plaster should be applied to intact, dry, non-irritated skin only, after the shingles rash has fully healed. The entire painful area should be covered once a day for up to 12 hours within a 24-hour period. You must then have a 12-hour period without a patch before applying the next one.

If needed, the patch may be cut into smaller pieces with scissors to fit the affected area, but do not use more than a total of three patches at the same time.

---

Q: What should I avoid when using Vessatis?

A: You should not use Vessatis:

• If you are allergic to lidocaine or other ingredients in the patch, or to other local anesthetics of the amide type (e.g., bupivacaine, prilocaine).
• On injured skin, open wounds, or unhealed shingles lesions.
• On or near the eyes or mouth, or on other mucous membranes.

---

Q: Are there any common side effects with Vessatis?

A: The most commonly reported side effects occur at the site of application and may include:

• Burning sensation
• Dermatitis (skin inflammation)
• Erythema (redness)
• Pruritus (itching)
• Rash
• Skin irritation
• Vesicles (small blisters)

If you experience severe irritation or a burning sensation while wearing the patch, it should be removed. Talk to your doctor if you have concerns about side effects.

How to Store and Dispose of Vessatis?

The storage and disposal of Vessatis (Lidocaine Patch) are strictly defined by regulatory requirements to ensure product stability and safety.

---

Official Storage Conditions

Vessatis must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). Do not store the patches in a refrigerator or freezer.

The patch must remain in its original sealed child-resistant package until the moment of application.

---

Child Safety and Disposal Protocol

Store Vessatis out of the sight and reach of children and pets.

Upon removal, the used patch must be immediately folded in half so that the adhesive sides stick to themselves. The folded patch must then be discarded into the trash. Do not flush patches down the toilet.